Core Viewpoint - Sunshine Nuohua (688621.SH) has received the acceptance notice from the National Medical Products Administration for the clinical trial application of its research project ABA001 injection, which aims to treat hypertension [1] Group 1: Product Overview - ABA001 injection is a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT) messenger RNA, utilizing an N-Acetylgalactosamine (GalNAc) delivery system to precisely deliver the drug to liver cells [2] - The drug works by silencing AGT mRNA through the siRNA interference mechanism, effectively blocking the synthesis of AGT protein and inhibiting the Renin-Angiotensin-Aldosterone System (RAAS) that raises blood pressure [2] - Non-clinical studies indicate that a dosage of 1 mg/kg can significantly lower blood pressure, demonstrating good tolerance in animals and high safety, with the potential for long-acting effects allowing administration every three months or six months [2]

Core Viewpoint - Sunshine Nuohe (688621.SH) has received the acceptance notice from the National Medical Products Administration for the clinical trial application of its research project ABA001 injection, which aims to treat hypertension [1] Group 1: Product Overview - ABA001 injection is a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT) messenger RNA (mRNA), utilizing an N-Acetylgalactosamine (GalNAc) delivery system to precisely deliver the drug to liver cells [2] - The drug works by silencing AGT mRNA through the siRNA interference mechanism, thereby blocking the synthesis of AGT protein and fundamentally inhibiting the role of the Renin-Angiotensin-Aldosterone System (RAAS) in raising blood pressure [2] - Non-clinical studies indicate that a dosage of 1 mg/kg can significantly lower blood pressure, with good animal tolerance and high safety, potentially allowing for long-acting effects with administration every 3 to 6 months [2]

Core Viewpoint - Sunshine Nuohe (688621.SH) has received the acceptance notice from the National Medical Products Administration for the clinical trial application of its research project ABA001 injection, which aims to treat hypertension [1]. Group 1: Product Overview - ABA001 injection is a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT) messenger RNA (mRNA), utilizing an N-Acetylgalactosamine (GalNAc) delivery system to precisely deliver the drug to liver cells [2]. - The drug works by silencing AGT mRNA through the siRNA interference mechanism, thereby blocking the synthesis of AGT protein and fundamentally inhibiting the role of the Renin-Angiotensin-Aldosterone System (RAAS) in raising blood pressure [2]. Group 2: Clinical and Non-Clinical Research - Clinical studies of a similar siRNA drug, Zilebesiran, have confirmed the effectiveness and safety of this mechanism, with a single dose showing sustained efficacy for 24 weeks [2]. - Non-clinical studies indicate that a dosage of 1 mg/kg can significantly lower blood pressure, with good tolerance observed in animals, suggesting a high safety profile [2]. - ABA001 injection is expected to offer long-acting blood pressure reduction effects, potentially allowing for administration every three months or six months, thus providing a better treatment option for hypertension patients [2].